Biotechnology
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Jan. 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-01-12 13:02
6840
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
Details of Initial Therapeutic Programs to be Shared at the 39th J.P. Morgan Healthcare Conference BOSTON, Jan. 11, 2021 /PRNewswire/ -- Valo Health LLC (Valo), the technology company working to transform the drug discovery and development process and accelerate the creation of life-changin...
2021-01-12 12:26
1970
DarwinHealth Scientists Publish Foundational Research Identifying Regulatory Mechanisms Controlling Cancer Cell States and Drug Response
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc., a New York-based biotechnology and cancer drug discovery company announces the January 11, 2021 online publication in Cell of a landmark paper, "A Modular Master Regulator Landscape Controls Cancer Transcriptional Identity,"[1,2] in whic...
2021-01-12 08:21
2228
MedSkin Solutions Dr. Suwelack AG Receives FDA 510(k) Clearance for MatriDerm® - Its Three-Dimensional Acellular Collagen Elastin Dermal Matrix Portfolio
MedSkin Solutions Dr. Suwelack AG announces receiving FDA 510(k) clearance for its flagship Med Care product portfolio MatriDerm®. HAMBURG, Germany, Jan. 12, 2021 /PRNewswire/ -- MatriDerm® is a single-use three-dimensional acellular dermal matrix composed of bovine collagen fibers and bovine el...
2021-01-12 04:38
1590
Caprion-HistoGeneX Acquires Clinical Logistics Inc., a Virtual Central Specimen Management CRO, and Expands its Support of Clinical Trials Specimen Logistics
MONTREAL, Jan. 7, 2021 /PRNewswire/ -- Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners, announced today the acquisition of Clinical Logistics Inc. ("CLI"), a Virtual Central Specimen Management CRO based inHalifax, Canada. The...
2021-01-07 21:20
2874
Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies
CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed$53.5 million Series B+ fina...
2021-01-07 20:31
2961
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
- Ocular Pain, a $10+ billion global market, with significant unmet medical need - License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies IRVINE, California, PARIS, HONG KONG, Jan. 7, 2021 /PRNewswire/ -- IACTA Pharmaceuticals, Inc...
2021-01-07 20:00
2556
Merck Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics
- Adds to Merck's lipid manufacturing expertise, providing an integrated offering across mRNA value chain - AmpTec's differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing - Diagnostics business focused on produ...
2021-01-07 17:00
4609
Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer
SHANGHAI, Jan. 6, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced th...
2021-01-06 21:54
6977
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
SHANGHAI, Jan. 6, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, announced today th...
2021-01-06 21:52
7056
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18
- DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment - Phase 2 results indicate that VGX-3100 can be a safe, tolerable and efficacious adjunct to current ...
2021-01-06 21:00
4464
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-01-06 20:24
6307
JOYSBIO's COVID-19 antigen test kit is capable of detecting the new SARS-COV-2 strain found in the United Kingdom and the United States
BINHAI, Tianjin, Jan. 6, 2021 /PRNewswire/ -- As the world watches a concerning new strain of SARS-COV-2 first identified in theUnited Kingdom, one global biotech company has announced that their antigen test kit can detect the variant. JOYSBIO Biotechnology Co.'s SARS-CoV-2 Antigen Rapid Test K...
2021-01-06 15:11
2721
Global Cord Blood Announces NHC Policy Update
HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported thatChina's National Health Commission ("NHC") ...
2021-01-05 20:30
11907
Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory
DAEJEON, South Korea and SHANGHAI, Jan. 5, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and theChina-based biopharmaceutical company 3D Medicines have entered into a License Agreement granting exclusive rights to develop, manufacture, and commercialize YBL-013, a T cell bi-sp...
2021-01-05 09:00
2644
Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies
SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Adm...
2021-01-05 08:32
3051
Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer
SHANGHAI and HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2021-01-05 08:00
3852
AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics' Newly Approved Libmeldy(TM)
SEATTLE, Jan. 4, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is the first manufacturer of Orchard Therapeutics' Libmeldy™, which was recently approved by the European Commission (EC) as a one-time therapy for ...
2021-01-04 22:30
4026
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
SHANGHAI and HONG KONG, Jan. 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2021-01-04 08:00
4554
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of ...
2020-12-31 22:38
8742
Week's Top Stories
Most Reposted
SGTraDex and IMDA Receive Pro-Enterprise Impact & Partnership Award for Interoperable Digital Documents Against Payment Trade Cooperation
[Picked up by 313 media titles]
2025-11-25 15:37
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 311 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 292 media titles]
2025-11-29 09:00
HOTEL GROOVE SHINJUKU strengthens its services for deaf and hard of hearing guests
[Picked up by 289 media titles]
2025-11-25 10:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 285 media titles]
2025-11-26 10:49
Most Read
LightInTheBox to Hold 2025 Annual General Meeting on December 19, 2025
2025-11-25 21:20
2714
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2247
